InflaRx NV PANAMO Ph3 Results Call Transcript
Hello. Thank you for joining us today for our presentation on the top line results from our Phase III Panama trial of Vilobelimab in severe COVID-19 patients. A replay will also be available on our website following the live event.
Before we begin, I'd like to point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These beliefs are subject to certain risks and uncertainties, and our actual results may differ materially.
I encourage you to consult the risk factors discussed in our SEC filings for more details. Our agenda today will include an introduction of key messages, a review of the Vilobelimab mode of action in COVID-19, the Panama trial design and Phase II results review; and finally, the Panamo Phase III trial results. We will conclude with a live Q&A session for which I will give instructions at the end of the presentation.
Today, I will be joined by our CEO, Professor Niels Riedemann; and our Chief Clinical Development Officer, Dr. Korinna Pilz. I will
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |